Home » Headlines » Currently Reading:

Morning Headlines 8/31/17

August 30, 2017 Headlines 2 Comments

AHA Letter To Representative Pat Tiberi

AHA writes a letter to Rep. Pat Tiberi (R-OH), Chairman of the Committee on Ways and Means’ Subcommittee on Health, calling for the cancellation of Meaningful Use Stage 3.

FDA approval brings first gene therapy to the United States

The FDA has approved CAR-T, a gene therapy treatment for certain types of pediatric leukemia, making it the first gene therapy approved for use in the US. Novartis developed the treatment and has put a $475,000 price tag on the drug, far below analyst expectations. In a clinical trial, a single dose of CAR-T left 83 percent of participants cancer free after three months.

Medtronic invests $40 million in robotics company Mazor

Medtronic announces that it has invested $40 million in surgical robot vendor Mazor Robotics, bringing its total investment in the company to $72 million. Medtronic will now become the exclusive distributor of Mazor’s robotic surgery system.

Aetna scoops up rising star from Wal-Mart’s health group to lead Apple Watch partnership

Aetna hires Walmart’s health division director Ben Wanamaker to lead its joint venture with Apple.

View/Print Text Only View/Print Text Only


HIStalk Featured Sponsors

     

Currently there are "2 comments" on this Article:

  1. Folks should remember that killing MU3 would hurt Medicaid providers much more than hospitals or Medicare EPs. The Medicaid program has a few more years of funding left in it. The other programs – for most hospitals and EPs – do not, and have shifted into the penalty phase.







Subscribe to Updates

Search


Loading

Text Ads


Report News and Rumors

No title

Anonymous online form
E-mail
Rumor line: 801.HIT.NEWS

Tweets

Archives

Founding Sponsors


 

Platinum Sponsors


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gold Sponsors


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reader Comments

  • Sam Lawrence: Except in this case, coding = medical billing, not development. Though the same warning may be true...
  • BeenThere: Partners will find the savings from their cuts of coders as fools gold. There are a lot of hidden costs running an outs...
  • JC: If there is not there can be. VistA has a reference lab interface that can create the manifests/labeling and such as we...
  • Tom Cornwell: Great stuff from Dr. Jayne as usual. One small typo, last sentence of second-to-last paragraph: should be 'who's' not 'w...
  • HIT Observer: What I find most interesting here, is people defending their common practices rather than truly taking this as invaluabl...
  • Bob: There's no incentive for the provider to spend time doing a price comparison for the patient. Nor is it a good use of th...
  • Peppermint Patty: Veteran - can you clarify what was "fake "? Was something made up (definition of fake) or did you disagree with Vapo...
  • Pat Wolfram: Such a refreshing article. Thanks -- there really can be a simpler version of an acute HIT implementation. But I do ...
  • Woodstock Generation: Bravo to HIStalk's Weekender recaps and other news/opinions. I read it first thing on Monday mornings..................
  • Veteran: #fakenews...

Sponsor Quick Links